Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient and Have Failed Prior Systemic Therapy.

Next Previous
Search
Trial Profile

A Phase 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient and Have Failed Prior Systemic Therapy.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegargiminase (Primary)
  • Indications Leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Polaris Pharmaceuticals

Most Recent Events

  • 08 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 04 Oct 2013 Status changed from active, no longer recruiting to recruiting as reported by M.D. Anderson Cancer Center.
  • 07 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top